sales@rootsanalysis.com | +1 (857) 387 7999 | +44 (748) 188 1310 | Login | Review Order 0
Now in beta · Powered by the Roots Analysis research library

Market intelligence
in seconds, not weeks.

LabKairos™ turns the Roots Analysis research library, a decade-plus of proprietary pharma, biotech, and healthcare studies into instant, sourced answers. It has been built for analysts, investors, and strategy teams who need the evidence behind every figure.

Try LabKairos™  → Book a 20-min demo
★★★★★ Trusted by 1,500+ pharma & life-sciences clients
🔒https://www.labkairos.com
History
Free Plan · Upgrade
LabKairos™
Ask anything...
Deep Research
Explainability
Suggested for you
What is the projected gene therapy market size through 2035?
How is the CAR-T manufacturing landscape evolving across Asia?
Who are the leading biopharma CMOs by manufacturing capacity?
Which ADC players have differentiated linker-payload IP?
Request Demo Invite Friends
01 · What makes LabKairos™ different

Three things only LabKairos™ offers.

An AI assistant is only as good as what it's grounded in. LabKairos™ is grounded in fifteen years of proprietary research

Proprietary Intellectual Capital: not the open web

Over a decade of Roots Analysis research across pharma, biotech, and healthcare - fully indexed and ready to be queried. The same studies that cost thousands of dollars in report form, answerable in seconds.

Roots Verified Research: every answer cites its source

Every claim resolves to a specific report, edition, and page - so the figure in your board deck survives the first hard question. We know how important it is to validate / back the findings.

Backed by Human Intelligence: a Roots expert behind every answer

LabKairos™ delivers answers to 95% of your questions. When you need custom research, forecasts, or deeper analysis, a Roots analyst takes over. AI speed. Human expertise.

02 · See how it works live

A sourced answer in four seconds.

A real query. A real retrieval trace. A real Roots Analysis report cited at the section level. This is the actual product - not a mockup.

🔒 https://www.labkairos.com/chat
Live
Retrieved from 250+ relevant reports
Global Gene Therapy Market (6th Ed)  ·  Cell & Gene Therapy Manufacturing (5th Ed)  ·  Rare Disease Therapeutics  ·  Viral Vector Manufacturing
Compiled insights from 12 passages across 4 reports
Finished · 1.2s
Market size and growth
Roots Verified Research
Global Gene Therapy Market (6th Edition)
Published June 2026 · Chapter 24 · Market Forecast · Page 754
"The global gene therapy market, valued at USD 4.20 billion in 2025, is projected to reach USD 6.07 billion in 2026 and USD 20.47 billion by 2035, with a 14.5% CAGR during the forecast period 2026 to 2035."
Access Full Report Now  →
03 · The data behind the answers

Knowledge base behind 1,500+ global clients

LabKairos™ transforms years of analyst work into a searchable intelligence layer, powering investment decisions, product strategy, and market entry for big pharma, start-ups, venture capital firms and universities / academic institutes

1.5M+
datapoints
Analyzed across different disease indications, target markets, regulatory guidelines and others
100+
markets
Major markets covered across pharma, biotech, life sciences, and beyond
60K+
companies
Profiled across pharma, biotech, medtech, and healthcare
10K+
experts
Information sourced from our global network of primary research experts
Cell & Gene Therapy Antibody-Drug Conjugate AI in Drug Discovery Precision Medicine RNA Therapeutic Biologics Manufacturing CRISPR and Gene Editing Organ-on-Chip Multiomics Synthetic Biology Bispecific Antibodies Cell Therapy Manufacturing Companion Diagnostics Drug Repurposing AI Agents in Pharma Biomarker Discovery mRNA Therapeutics Microbiome Therapeutics Peptide Therapeutics Nanomedicine Exosome Therapeutics Spatial Biology Digital Biomarkers Continuous Bioprocessing Protein Engineering Cell & Gene Therapy Antibody-Drug Conjugate AI in Drug Discovery Precision Medicine RNA Therapeutic Biologics Manufacturing CRISPR and Gene Editing Organ-on-Chip Multiomics Synthetic Biology Bispecific Antibodies Cell Therapy Manufacturing Companion Diagnostics Drug Repurposing AI Agents in Pharma Biomarker Discovery mRNA Therapeutics Microbiome Therapeutics Peptide Therapeutics Nanomedicine Exosome Therapeutics Spatial Biology Digital Biomarkers Continuous Bioprocessing Protein Engineering
04 · Built for the people who use it

One question. Three different answers.

An analyst, an investor, and a strategy lead need different evidence from the same data. LabKairos™ gives you the answer as per your role.

PHARMA & BIOTECH STRATEGY

Market sizing without the two-week scavenger hunt.

Instantly access the market data behind every sizing assumption to better understand industry growth rates, market drivers, regional splits and other market signals.

Example Query
›What is the projected APAC GLP-1 market size by 2032, broken down by indication?
PE & VC INVESTMENT TEAMS

Sector diligence in hours, not weeks.

Fast-screen niche markets you can't afford to miss. Pipeline density, white-space mapping, and competitive positioning, structured for investment decision-making.

Example Query
›Which Series-B-stage cell therapy companies have differentiated manufacturing IP?
CORPORATE DEVELOPMENT and M&A

TAM validation that survives the deal room.

Benchmark adjacent markets, validate growth assumptions, and compare opportunities across geographies before committing resources to a transaction.

Example Query
›Compare the addressable market for surgical robotics in EU vs. US over the next 5 years.
05 · Built for what comes next

Every answer, ready for the boardroom.

Download any LabKairos™ answer as a branded, sourced, audit-ready report. Drop it in a deck without
the need for manual repackaging.

Co-branded by default
LabKairos™ lockup and Powered by Roots Analysis baked into the page header. You benefit from this brand equity without paying any royalties.
Structure preserved, not flattened
Tables, sub-headers, bullets, regional breakdowns - exported as layout, not pasted text. Drops straight into your executive presentations.
Sources, numbered and complete
Every cited Roots Analysis report listed by title and edition. The same numbering as the in-line citations - auditable end to end.
Audit-ready by construction
Confidential mark, methodology note, and list of key assumptions clearly listed. Review teams will not send it back.
Download PDF
Powered by Roots Analysis
Recent Fundings

There are several recent rounds of funding, some of the prominent recent rounds are highlighted in the table below. [Source 1]

Company
Date
Amount
Type
Lead Investors
SonoThera
June 2026
$125 million
Series B
Vida Ventures and Others
Latus Bio
May 2026
$97 million
Series A
8VC (extension lead), DCVC Bio
Opus Genetics
Apr 2026
Up to $155 million
Non-dilutive note facility
Oberland Capital
AAVantgarde Bio
Nov 2025
$141 million
Series B
Schroders (lead); Atlas Venture, Forbion, Amgen Ventures
Kriya Therapeutics
Sep 2025
$320 million
Series D
Patient Square Capital & Premji Invest (co-leads); Peter Thiel
Deals: mergers, acquisitions and partnerships

The deal market is split: big pharma is buying de-risked assets cheaply, while strained developers exit via distressed sales and take-privates.

  • Lilly bought Adverum (wet AMD gene therapy) at a discount, up to ~$261M (Oct 2025).
  • BioMarin acquired Inozyme (ENPP1, Phase 3), May 2025. REGENXBIO partnered Nippon Shinyaku on MPS II/I: $110M upfront, up to $700M milestones.
  • bluebird bio taken private; plus a ~$2.4B in vivo cell-therapy buyout and a Gilead cell-therapy deal in early 2026.
Sources
  • Gene Therapy Market, 6th edition
  • Cell Therapy Market, 5th edition
  • Viral Vector Manufacturing Market, 3rd edition
Disclaimer

This document has been generated using LabKairos™, an AI-augmented research and analysis platform developed by Roots Analysis. The insights presented are based on a synthesis of publicly available information, proprietary analytical frameworks, and algorithmic interpretation. While every effort has been made to ensure accuracy and relevance, this document is intended to support strategic discussions and should not be relied upon as a substitute for independent validation or primary research.

⚗ Roots Analysis · Confidential Page 2 of 2
LabKairos™
LabKairos™ Insight Report
Query Topic: Trends in Gene Therapy
Generated On: June 20 · 10:38 AM UTC
Query Overview
User Query: What are the current market trends in gene therapy?
Query Output

Gene therapy is in a sustained growth phase, driven by a maturing approval pipeline, a shift toward one-time curative treatments, and steady advances in delivery technology.

Market size and growth

The global gene therapy market is valued USD 6.07 billion in 2026 and estimated to reach USD 20.47 billion by 2035, growing at a CAGR of 14.5% over the forecast period (2026 to 2035) Source 1, Source 2.

Regulatory momentum: approvals and launches
  • Otarmeni (Regeneron) received accelerated FDA approval in April 2026 as the first-ever gene therapy for OTOF-related genetic hearing loss.
  • RP-A501 (Rocket Pharmaceuticals) was approved by the FDA in March 2026 for Danon disease, a rare and often fatal cardiac condition.
  • Zevaskyn became the first gene therapy approved for RDEB in 2025.
⚗ Roots Analysis · Confidential Page 1 of 2
← Scroll to see both pages →
06 · Where LabKairos™ sits

The intelligence of an enterprise platform.
Without the enterprise contract.

A comparison of how LabKairos™ differs from generic AI tools when accuracy, traceability, and domain expertise matter.

Feature
Other AI Tools
LabKairos™
Knowledge source
✕ Open internet · public web
Proprietary Roots library
Source citation
✕ Often missing or unreliable
Every figure cites report + page
Domain expertise
✕ General-purpose
Pharma · biotech · life sciences
Hallucination risk
✕ Confident wrong answers
Constrained to retrieved passages
Privacy / deployment
✕ Queries sent to vendor cloud
Self-hosted option for regulated clients
Procurement
✕ Variable - often opaque
Try before you buy
Suitable for board / IC use
✕ Risky - can't verify
Yes - every answer is auditable
← Scroll to see full table →
07 · From Roots Analysis clients

Fifteen years of research, vouched for.

LabKairos™ inherits the trust earned by Roots Analysis.

“

Roots reports are stuffed with actionable detail with high-level insights to support critical business decisions.

Vice President, Global Commercialization
A US-based medical device manufacturer
“

Reports from Roots Analysis are far superior to other reports I have acquired in this price range over the last 20 years.

Vice President
A medical device manufacturer · United States
“

I am impressed with the thoroughness of the report and in-depth analysis of various market segments.

Strategy Director
A large biotech firm · Switzerland
“

Your research and analysis are highly relevant to our work; you have also covered areas that we do not get from other firms.

Director
A global biopharmaceutical company · United States
08 · Built for regulated environments

Your queries don't leave your environment.

Whether you're assessing markets, competitors, or growth opportunities, LabKairos™ is built to keep your research process private, protected, and under your control.

Lab Kairos Certifications
ISO 9001
ISO
9001
ISO 9001
Quality management
ISO 27001
ISO
27001
ISO 27001
Information security
ESOMAR
ESOMAR
ESOMAR
World research member
GDPR
🛡 GDPR
GDPR
EU data ready
AIRS
AIRS
AIRS
Internet research
★  THE FASTEST WAY TO START

Ask the question.
Get the answer.

Five free queries. No credit card. No procurement. Just open the chat and try the question your team has been wrestling with all week.

Try LabKairos™  → Book a 20-min demo
Enterprise plans available · Self-hosted deployment for regulated teams